Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102206 · ClinicalTrials.gov registry record · Phase 2
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00102206 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 6 participants.
The verdict
NCT00102206, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.
Interventions
- DRUG Lamivudine
- DRUG Saquinavir
- DRUG Emtricitabine
- DRUG Abacavir sulfate
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102206
The ClinicalTrials.gov registry entry for NCT00102206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00102206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102206 about?
NCT00102206 is a clinical study titled "A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy". HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcript...
What is the current status of trial NCT00102206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00102206?
The interventions under investigation include: Lamivudine (DRUG), Saquinavir (DRUG), Emtricitabine (DRUG), Abacavir sulfate (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00102206?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.